CKPT Stock Price, Checkpoint Therapeutics Quote, Chart

Market Summary

USD1.87+0.09

Delayed

5.06%

CKPT Stock Price

View Fullscreen

CKPT RSI Chart

CKPT Valuation

Market Cap

65.4M

Price/Earnings (Trailing)

-1.25

Price/Sales (Trailing)

635.19

Price/Free Cashflow

-1.63

CKPT Price/Sales (Trailing)

CKPT Profitability

Return on Equity

510.42%

Return on Assets

-436.89%

Free Cashflow Yield

-61.19%

CKPT Fundamentals

CKPT Revenue

Revenue (TTM)

103.0K

Rev. Growth (Yr)

-91.89%

Rev. Growth (Qtr)

-80.65%

CKPT Earnings

Earnings (TTM)

-52.3M

Earnings Growth (Yr)

-4.5%

Earnings Growth (Qtr)

42.78%

Breaking Down CKPT Revenue

Last 7 days

24.7%

Last 30 days

12.0%

Last 90 days

-7.0%

Trailing 12 Months

-31.9%

How does CKPT drawdown profile look like?

CKPT Financial Health

Current Ratio

0.54

CKPT Investor Care

Shares Dilution (1Y)

165.03%

Diluted EPS (TTM)

-2.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	175.0K	188.0K	171.0K	103.0K
2022	252.0K	115.0K	134.0K	192.0K
2021	165.0K	278.0K	279.0K	268.0K
2020	2.3M	1.3M	1.1M	1.1M
2019	3.5M	4.4M	4.7M	1.7M
2018	1.4M	1.2M	807.0K	3.5M
2017	3.0M	2.1M	1.9M	1.7M
2016	1.1M	1.6M	2.1M	2.6M
2015	0	0	0	590.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Checkpoint Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 20, 2024	fortress biotech, inc.	acquired	-	-	193,905	-
Feb 28, 2024	oliviero james f iii	sold	-12,141	2.06	-5,894	ceo, president and director
Feb 28, 2024	oliviero james f iii	gifted	-	-	-9,056	ceo, president and director
Feb 28, 2024	gray william garrett	sold	-4,212	2.07	-2,035	chief financial officer
Feb 01, 2024	gray william garrett	sold	-8,024	1.95	-4,115	chief financial officer
Feb 01, 2024	oliviero james f iii	gifted	-	-	-12,950	ceo, president and director
Feb 01, 2024	oliviero james f iii	sold	-23,919	2.01	-11,900	ceo, president and director
Dec 29, 2023	fortress biotech, inc.	acquired	-	-	158,134	-
Sep 25, 2023	fortress biotech, inc.	acquired	-	-	80,906	-
Aug 16, 2023	oliviero james f iii	gifted	-	-	-12,510	ceo, president and director

Which funds bought or sold CKPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-92,839	-	-%
May 16, 2024	B. Riley Wealth Advisors, Inc.	reduced	-69.91	-290,517	83,555	-%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-22.72	-99,195	222,655	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-14,526	124,074	-%
May 15, 2024	MORGAN STANLEY	added	31.61	3,304	21,853	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-57.00	-	-%
May 15, 2024	TITLEIST ASSET MANAGEMENT, LLC	new	-	35,875	35,875	0.01%
May 15, 2024	Cetera Investment Advisers	sold off	-100	-32,855	-	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-27,049	-	-%
May 15, 2024	Engineers Gate Manager LP	sold off	-100	-40,943	-	-%

Are Funds Buying or Selling CKPT?

Are funds buying CKPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CKPT

No. of Funds

Unveiling Checkpoint Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 22, 2024	fortress biotech, inc.	7.5%	2,796,278	SC 13D/A
Feb 14, 2024	armistice capital, llc	9.99%	2,715,635	SC 13G/A
Sep 26, 2023	fortress biotech, inc.	11.3%	2,444,239	SC 13D/A
Jul 06, 2023	fortress biotech, inc.	13.6%	2,363,333	SC 13D/A
Apr 19, 2023	fortress biotech, inc.	17.5%	2,281,927	SC 13D/A
Feb 14, 2023	armistice capital, llc	9.99%	987,211	SC 13G
Jan 13, 2023	fortress biotech, inc.	19.3%	2,203,713	SC 13D/A
May 07, 2021	blackrock inc.	4.8%	3,487,614	SC 13G/A
Feb 16, 2021	cvi investments, inc.	-	636,964	SC 13G/A
Feb 02, 2021	blackrock inc.	5.3%	3,240,599	SC 13G

Recent SEC filings of Checkpoint Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	SC 13D/A	13D - Major Acquisition
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 14, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	8-K	Current Report

Peers (Alternatives to Checkpoint Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Checkpoint Therapeutics Inc News

Latest updates

Checkpoint Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-80.6%	6.00	31.00	31.00	35.00	74.00	48.00	18.00	52.00	16.00	29.00	155	68.00	27.00	28.00	42.00	972	25.00	280	1,051	352	3,031
Operating Expenses	31.6%	10,175	7,732	16,226	18,118	16,718	10,712	14,182	16,913	29,786	11,307	9,312	6,586	10,269	4,972	4,716	4,313	8,882	5,514	5,878	6,284	14,923
S&GA Expenses	-16.1%	1,876	2,236	2,281	2,292	2,482	1,846	2,129	2,243	2,128	1,923	2,114	2,373	2,124	2,429	1,687	1,678	2,152	1,620	1,758	1,703	1,502
R&D Expenses	51.0%	8,299	5,496	13,945	15,826	14,236	8,866	12,053	14,670	27,658	9,384	7,198	4,213	8,145	2,543	3,029	2,635	6,730	3,894	4,120	4,581	13,421
Net Income	-234.2%	-19,128	-5,724	-16,521	-10,474	-21,022	-10,612	-14,142	-16,848	-29,756	-11,265	-9,144	-6,505	-10,225	-4,930	-4,645	-3,281	-8,826	-5,206	-4,792	-5,890	-11,619
Net Income Margin	-60.2%	-503.37*	-314.27*	-311.86*	-321.43*	-326.17*	-532.52*	-626.18*	-265.92*	-211.46*	-133.11*	-110.81*	-159.42*	-21.59*	-20.32*	-16.65*	-9.50*	-14.47*	-5.84*	-7.13*	-9.53*	-10.37*
Free Cashflow	53.7%	-6,833	-14,750	-11,976	-14,031	-15,300	-11,417	-11,231	-19,606	-9,478	-6,463	-5,708	-4,657	-4,934	-4,916	-2,161	-4,540	-4,729	-3,486	-4,955	-8,203	-7,605

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	122.7%	12.00	5.00	2.00	8.00	6.00	13.00	22.00	32.00	43.00	56.00	61.00	66.00	61.00	43.00	43.00	23.00	23.00	27.00	14.00	15.00	15.00
Current Assets	122.7%	12.00	5.00	2.00	8.00	6.00	13.00	22.00	32.00	43.00	56.00	61.00	66.00	61.00	43.00	43.00	23.00	23.00	27.00	14.00	15.00	15.00
Cash Equivalents	128.1%	11.00	5.00	2.00	7.00	5.00	12.00	20.00	31.00	41.00	55.00	60.00	65.00	60.00	41.00	42.00	22.00	21.00	26.00	13.00	13.00	14.00
Liabilities	20.6%	22.00	18.00	21.00	32.00	28.00	33.00	23.00	25.00	23.00	26.00	13.00	9.00	7.00	7.00	6.00	8.00	7.00	8.00	8.00	8.00	8.00
Current Liabilities	20.6%	22.00	18.00	21.00	32.00	28.00	33.00	23.00	25.00	23.00	26.00	13.00	9.00	7.00	7.00	6.00	8.00	7.00	8.00	8.00	8.00	8.00
Shareholder's Equity	21.4%	-10.25	-13.05	-	-	-22.18	-19.48	-	7.00	20.00	30.00	48.00	57.00	54.00	35.00	36.00	15.00	16.00	19.00	6.00	7.00	7.00
Retained Earnings	-3.5%	-325	-314	-295	-289	-273	-262	-241	-230	-216	-199	-170	-158	-149	-143	-133	-128	-123	-120	-111	-106	-101
Additional Paid-In Capital	4.6%	312	298	276	266	251	241	240	238	237	223	218	216	204	174	169	143	137	136	118	113	108
Shares Outstanding	29.4%	35.00	27.00	22.00	17.00	13.00	10.00	9.00	9.00	9.00	8.00	7.00	8.00	7.00	6.00	5.00	5.00	5.00	5.00	3.00	3.00	3.00
Float	-	-	-	-	33.00	-	-	-	71.00	-	-	-	185	-	-	-	81.00	-	-	-	69.00	-

Cashflow (Last 12 Months)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	5.3%	-6,474	-6,833	-14,750	-11,976	-14,031	-15,300	-11,417	-11,231	-19,606	-9,478	-6,463	-5,708	-4,657	-4,934	-4,916	-2,161	-4,540	-4,729	-3,486	-4,955	-8,203
Share Based Compensation	5.5%	709	672	689	567	969	639	781	729	775	818	779	766	774	685	725	731	639	677	833	813	798
Cashflow From Financing	28.0%	12,787	9,989	9,101	14,551	6,809	6,890	1,008	642	6,347	4,010	1,542	10,799	23,918	3,677	25,021	2,604	-56.00	17,746	3,341	4,013	355

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CKPT Income Statement

2024-03-31

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended
Condensed Statements of Operations - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Condensed Statements of Operations
Revenue - related party		$ 35
Operating expenses:
Research and development	$ 8,497	15,826
General and administrative	2,451	2,292
Total operating expenses	10,948	18,118
Loss from operations	(10,948)	(18,083)
Other income:
Interest income	4	43
Gain on common stock warrant liabilities		7,566
Foreign currency exchange loss	(1)
Total other income	3	7,609
Net Loss	$ (10,945)	$ (10,474)
Loss per Share:
Basic net loss per common share outstanding	$ (0.33)	$ (0.89)
Diluted net loss per common share outstanding	$ (0.33)	$ (0.89)
Basic weighted average number of common shares outstanding	32,930,977	11,749,139
Diluted weighted average number of common shares outstanding	32,930,977	11,749,139

CKPT Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 11,241	$ 4,928
Prepaid expenses and other current assets	734	450
Total current assets	11,975	5,378
Total Assets	11,975	5,378
Current Liabilities:
Accounts payable and accrued expenses	19,159	15,485
Accounts payable and accrued expenses - related party	2,941	2,815
Common stock warrant liabilities	125	125
Total current liabilities	22,225	18,425
Total Liabilities	22,225	18,425
Commitments and Contingencies (note 5)
Stockholders' Equity (Deficit)
Common stock issuable, 1,492,915 shares as of March 31, 2024 and December 31, 2023	3,419	3,419
Additional paid-in capital	311,605	297,864
Accumulated deficit	(325,278)	(314,333)
Total Stockholders' Equity (Deficit)	(10,250)	(13,047)
Total Liabilities and Stockholders' Equity (Deficit)	11,975	5,378
Common No Class
Stockholders' Equity (Deficit)
Common Stock Value	$ 4	$ 3

About Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CEO	Mr. James F. Oliviero III, C.F.A., CFA
WEBSITE	checkpointtx.com
INDUSTRY	Biotechnology
EMPLOYEES	24

Checkpoint Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Checkpoint Therapeutics Inc? What does CKPT stand for in stocks?

CKPT is the stock ticker symbol of Checkpoint Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Checkpoint Therapeutics Inc (CKPT)?

As of Fri May 17 2024, market cap of Checkpoint Therapeutics Inc is 65.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CKPT stock?

You can check CKPT's fair value in chart for subscribers.

What is the fair value of CKPT stock?

You can check CKPT's fair value in chart for subscribers. The fair value of Checkpoint Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Checkpoint Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CKPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Checkpoint Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CKPT is over valued or under valued. Whether Checkpoint Therapeutics Inc is cheap or expensive depends on the assumptions which impact Checkpoint Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CKPT.

What is Checkpoint Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CKPT's PE ratio (Price to Earnings) is -1.25 and Price to Sales (PS) ratio is 635.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CKPT PE ratio will change depending on the future growth rate expectations of investors.